MedTrace Logo

Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)

NCT03812302 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-10-18

No results posted yet for this study

Summary

The aim of this study is to compare the use of FDG PET/CT to Ga-68 HA-DOTATATE (abbreviated DOTATATE) PET/CT in patients with active giant cell arteritis (GCA) started on prednisone to understand if DOTATATE can identify more areas of active blood vessel inflammation than FDG.

Conditions

  • Giant Cell Arteritis

Interventions

DIAGNOSTIC_TEST

68-Ga HA-DOTATATE PET/CT

See arm description.

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Alison Clifford · University of Alberta

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-09
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03812302 on ClinicalTrials.gov